Loading...
At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2013), held May 31 through June 5 in Chicago, specialists discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were in attendance to report highlights of the conference. Here, David Ilson, MD, reviews key presentations on new gastrointestinal cancer treatments.
Von Hoff and colleagues reported results from the phase III, randomized IMPACT trial (Abstract 4005), which compared conventional gemcitabine therapy with nanoparticle albumin-bound (nab)-paclitaxel plus gemcitabine in 861 patients with advanced pancreatic cancer. Patients received either gemcitabine …